Destination: Cure

Cure Research with a Heart Translation inhibitors may be part of a therapeutic strategy by Jeannie Wraight To date there are over 100 documented cases of HIV...

Hiding Place One focus of the amfAR 2016 CURE Summit targeted HIV reservoirs by Jeannie Wraight This year, amfAR marked World AIDS Day with the 2016 HIV...

Step Forward Vaccine candidates like HTVN 702 are needed to build momentum by Jeannie Wraight If current HIV diagnoses rates persist, about 1 in 2 black men...

LifeGuide Good News, Bad News The HIV cure front faces disappointment mixed with hope by Jeannie Wraight The past year has been a difficult one in the HIV...

by Jeannie Wraight As part of the Countdown to a Cure Initiative, amfAR (The Foundation for AIDS Research) will direct $20 million, of a $100...

LifeGuide Cure—or Bust Amid advances and setbacks in care, we must still aim for the end of HIV by Jeannie Wraight   I recently read a rather angry reader...

Fast Look Cure research highlights from CROI 2018 by Jeannie Wraight The Conference on Retroviruses and Opportunistic Infections (CROI) provides an annual snapshot of the year’s most...

JAK of All Trades Researchers look to JAK inhibitors as part of hiv treatment & eradication by Jeannie Wraight R research on three Janus kinase inhibitors (JAK...

A Plan for America The Trump administration strives to end the HIV epidemic, but at whose expense? by Jeannie Wraight In this month’s Destination: Cure I’m going...

GlaxoSmithKline (GSK) and the University of North Carolina at Chapel-Hill (UNC) will launch a jointly owned novel HIV Cure Center, as well as a...